Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

Dial-in information: North America (toll free): 1-866-713-8310 International: 1-617-597-5308 Enter passcode: 82004406

The call will be available for replay until Wednesday, July 5, 2007 by calling 1-888-286-8010 (North America) or 1-617-801-6888 (International) and entering the pass code 55009709. A live webcast will also be available to all interested parties on Aspreva's website: http://www.aspreva.com. Please click on the "Webcasts and Events" link under the Investors section of Aspreva's website. A replay of the webcast will be available until the Company's second quarter 2007 conference call.

About CellCept

CellCept (mycophenolate mofetil, MMF) is an immunosuppressant or anti-rejection drug approved for use in combination with other immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients receiving kidney, heart and liver transplants. There are no adequate and well-controlled studies in pregnant women. As CellCept has been shown to have teratogenic effects in animals at subclinical doses on a body surface area basis, it may cause fetal harm when administered to a pregnant woman. CellCept should not be used in pregnant women unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to beginning therapy even where there has been a history of infertility, unless due to hysterectomy. Women of childbearing potential must use effective contraception before beginning CellCept therapy, during therapy and for six weeks following discontinuation of therapy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy occurs during treatment, the physician and patient should discuss the desirability of continuing the
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/1/2008)...ecember 9 at 11:00 am ET to Discuss Phase 2 Study ... Calif., Dec. 1 Sunesi...armaceutical company focused on the development an...today announced new data from its studies of vorel...nted during the 50th American Society of Hematolog...
(Date:11/28/2008)...ire/ -- German biotech company,Partec is expandin...ing and,AIDS patient follow-up diagnostics for de..., 2.5 million patient tests have been performed wi...Flow" system, supporting already,more than 1 mill...on of the,Partec innovation, the average cost of ...
(Date:11/26/2008)...RANKLIN, Mass., Nov. 26 ...nced today that it has received full approval from...ts U.S. pivotal trial to study the effectiveness o...ted therapy in the prevention of Contrast-Induced ...d PLC,s request to expand their investigation from...
(Date:11/25/2008)...swire-FirstCall/ -- Poniard,Pharmaceuticals, Inc....cused on,innovative oncology therapies, announced...atives for its preclinical research programs in or...n the clinical development of picoplatin,its lea...mmercialization of,picoplatin in the treatment of...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3ExonHit Therapeutics 2007 Financial Results 3736 1ExonHit Therapeutics 2007 Financial Results 3736 2ExonHit Therapeutics 2007 Financial Results 3736 3ExonHit Therapeutics 2007 Financial Results 3736 4ExonHit Therapeutics 2007 Financial Results 3736 5ExonHit Therapeutics 2007 Financial Results 3736 6ExonHit Therapeutics 2007 Financial Results 3736 7ExonHit Therapeutics 2007 Financial Results 3736 8ExonHit Therapeutics 2007 Financial Results 3736 9ExonHit Therapeutics 2007 Financial Results 3736 10ExonHit Therapeutics 2007 Financial Results 3736 11ExonHit Therapeutics 2007 Financial Results 3736 12Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 1Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 2New Findings Support Alternatives to Pap Test 13540 1New Findings Support Alternatives to Pap Test 13540 2New Findings Support Alternatives to Pap Test 13540 3New Findings Support Alternatives to Pap Test 13540 4AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 1AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 2
(Date:12/2/2008)...RNewswire/ -- MedPro Imaging, a premier provider,...d the appointment of three,new ultrasound sales p...ve,expansion. The company also announced the rel...due to substantial growth throughout 2008. Keith,...nt of Sales and Marketing in,February of this yea...
(Date:12/2/2008)... keep driving safe, research shows , , T... on a cell phone are more distracted and more pron...d sitting next to them in the car, a new report fi...oint attention, so when you have a person sitting ...erson actually understands something about traffic...
(Date:12/2/2008)..., Kessler Foundation continues to improve the live...ST ORANGE, N.J.Dec. 2 One of the l... disabilities, Henry H. Kessler Foundation, announ...oundation. The Foundation is also changing the nam... Research Center and Kessler Foundation Program Ce...
(Date:12/2/2008)...lf Have Skipped Medical Care Due to Cost Issues- ,...swire/ -- A new survey released today by the Natio...hts another troubling aspect of the current financ...care for themselves or their families to save mone...ir health has gotten worse over the past five year...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4
...Carolina at Chapel Hill, in the current issue of P... may be possible molecular origin of at least nine... These neuro degenerative diseases, including Hunt...posit of proteins inside nerve cells. This deposit...
...logged arteries leading to a condition of early at...n the current issue of Psychosomatic Medicine. How...any such tendencies, said the study. The researche...and had found increased thickness of the lining of...
...he journal Antimicrobial Agents and Chemotherapy p...s that occur in the human saliva can lead to new w...y in children. Researchers at the University of Wa...ne a possible correlation between dental caries (t...
...l death for elderly people. A new study conducted ...s are four times more likely to fall than those wh...e are estimated to have type 2 diabetes, and the n... people by 2025. Previous investigations have def...
Other Medicine News:
Herpes Simplex Virus 2 IgG ELISA.
Cytomegalovirus IgM ELISA.
Small Incision Microforceps: Tano ILM Forceps
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling
Medicine Products: